Access cutting-edge uveal melanoma treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.
Access uveal melanoma specialists in Washington Dc at no cost
This study follows strict safety protocols and ethical guidelines
All study-related uveal melanoma treatment provided free
The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.
Sponsor: Replimune Inc.
Check if you qualify for this uveal melanoma clinical trial in Washington Dc, DC
If you're searching for uveal melanoma treatment options in Washington Dc, DC, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced uveal melanoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.